Both in vitro experimental results and in vivo small animal experimental results with mouse-bearing MDA-MB-231 tumor indicate that anti-CXCR4-NaGdF4 NDs exhibit good tumor-targeted ability and biotherapeutic efficacy of tumor. This evidence concerns the gene CXCR4 and neoplasm.